Shots: The P-III study involves assessing of PH94B vs PBO in 22 patients with Social Anxiety Disorder P-III study results: @1wk. decrease in average peak Subjective Units of Distress scores; […]readmore
Tags : Social Anxiety Disorder
Shots: Pherin will receive $2.25M of unregistered common stock (1,630,435 unregistered shares) from Vista VistaGen has rights to commercialize and develop PH94B nasal spray (expected to enter in P-III in […]readmore